Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950343 | 0.86 | ACLY (0.45) | GPR35TTRALBACLYRORC | |
| SCHEMBL2309558 | 0.86 | GPR35 (0.38) | GPR35TTRALBACACBACLY | |
| SCHEMBL20944039 | 0.79 | GPR35 (0.47) | GPR35ACACBTUBB1RORC | |
| SCHEMBL29159716 | 0.78 | KIF11 (0.37) | GPR35TTRALB | |
| SCHEMBL14658868 | 0.77 | ACACB (0.36) | ACACBTUBB1PDGFRBPDGFRADBH | |
| SCHEMBL3527606 | 0.77 | ACACB (0.39) | ACACBTUBB1PDGFRBPDGFRADBH | |
| SCHEMBL29582124 | 0.77 | EPAS1 (0.40) | TTRALB | |
| SCHEMBL5018947 | 0.77 | TRPV4 (0.38) | GPR35TTRALBTUBB1 | |
| SCHEMBL14871817 | 0.77 | AR (0.40) | GPR35TTRALBTUBB1GRM5 | |
| SCHEMBL31255629 | 0.77 | HRH3 (0.38) | GPR35GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117613388-B | Electrolyte and sodium ion battery | 湖州超钠新能源科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117613388-A | Electrolyte and sodium ion battery | 湖州超钠新能源科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117613388-B | Electrolyte and sodium ion battery | 湖州超钠新能源科技有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117613388-A | Electrolyte and sodium ion battery | 湖州超钠新能源科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-9187478-B2 | Substituted naphthyridines and their use as medicaments | Boehringer Ingellheim International GmbH (DE) | 2015-11-17 | — | — | US | disclosed |
| EP-2528915-B1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-10-28 | — | — | EP | disclosed |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-8969568-B2 | Substituted naphthyridines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-2528915-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| EP-0288488-A4 | DOPAMINE- -HYDROXYLASE INHIBITORS | — | 1990-09-12 | — | — | EP | disclosed |
| WO-1989006125-A1 | 4-ARALKYL-5-SUBSTITUTED-1,2,4-TRIAZOLE-5-THIOLS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0323737-A1 | 4-Aralkyl-5-substituted-1,2,4-triazole-5-thiols | SMITHKLINE BEECHAM CORPORATION (US) | 1989-07-12 | — | — | EP | disclosed |
| US-4810811-A | CHEMICAL INTERMEDIATES | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0288488-A1 | DOPAMINE- -HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0260814-A1 | Dopamine-Beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1988-03-23 | — | — | EP | disclosed |
| WO-1988001267-A1 | DOPAMINE-ss-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-02-25 | — | — | WO | disclosed |
| US-4707488-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0191621-A2 | Dopamine-bêta-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028939-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | GPR35 1865/4885TTR 2444/4885ALB 3349/4885 |
| US-20150126503-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS MEDICAMENTS | NR4A3, NR0B1, NR4A1 | GPR35 1865/4885TTR 2444/4885ALB 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.